TransMedics Group (NASDAQ:TMDX) Trading Up 8.2% - Here's What Happened

Key Points

• TransMedics Group's stock price increased by 8.2% on Thursday, reaching a high of $116.69, though the trading volume fell significantly to approximately 429,055 shares, down 67% from the average.
• Several analysts have raised their target prices for the stock, with Oppenheimer increasing it to $150.00, reflecting a general positive outlook on TransMedics Group, which has an average rating of "Moderate Buy."
• The company reported 37.7% year-over-year revenue growth with earnings per share of $0.92, surpassing analysts' estimates and showcasing strong operational performance.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) were up 8.2% on Thursday . The stock traded as high as $116.69 and last traded at $116.62. Approximately 429,055 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 1,305,038 shares. The stock had previously closed at $107.79.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TMDX shares. Oppenheimer upped their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Morgan Stanley upped their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Finally, Stifel Nicolaus started coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $122.11.

TransMedics Group Stock Up 9.5%

The firm's 50-day moving average price is $116.66 and its 200 day moving average price is $104.74. The firm has a market cap of $4.02 billion, a P/E ratio of 61.59 and a beta of 2.18. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Osaic Holdings Inc. boosted its holdings in shares of TransMedics Group by 48.5% in the second quarter. Osaic Holdings Inc. now owns 21,116 shares of the company's stock valued at $2,830,000 after acquiring an additional 6,899 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of TransMedics Group by 0.9% in the second quarter. Thrivent Financial for Lutherans now owns 24,879 shares of the company's stock valued at $3,334,000 after acquiring an additional 227 shares in the last quarter. State of Wyoming bought a new position in shares of TransMedics Group in the second quarter valued at approximately $76,000. Caxton Associates LLP bought a new position in shares of TransMedics Group in the second quarter valued at approximately $242,000. Finally, Public Sector Pension Investment Board boosted its holdings in shares of TransMedics Group by 8.3% in the second quarter. Public Sector Pension Investment Board now owns 115,335 shares of the company's stock valued at $15,456,000 after acquiring an additional 8,855 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.